Rules by state

Regenerative Medicine Laws by State

What every state’s rules say about who does what, and about stem cell and regenerative products. Sourced and dated, as of September 2026.

Request a date now
See all courses

Let’s say a patient asks you about a stem cell product. Is it legal where you practice? It depends on the source, the processing, what you claim and which state you’re in.

This page is how we read the rules as of September 2026, with every source linked. Your licensing board is the authority on your scope, and none of this is legal advice. The rules change every year, so check the source before you act on any of it.

Scales of justice beside an open book and a tablet on a dark desk

The federal rules apply in every state, not just some.

Start here. State law sits on top of these rules. It does not replace them.

361 or 351

Under 21 CFR 1271.10(a), a human cell or tissue product (an HCT/P) is regulated only under section 361 of the Public Health Service Act when it meets four criteria. It is minimally manipulated. It is for homologous use only, “as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” It is not combined with another article, with narrow exceptions. And it either has no systemic effect, or it is for autologous use, use in a first or second degree blood relative, or reproductive use. A product that fails those criteria is regulated as a biologic and needs FDA approval. Source

What is not an HCT/P

21 CFR 1271.3(d) leaves some things out of the HCT/P definition, including whole blood and blood components. That is why PRP, prepared from a patient’s own blood, is not regulated as an HCT/P. Source

FDA guidance, July 2020

FDA’s guidance on how it reads those criteria is “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use,” issued July 2020. Source

Expanded Access

Expanded access, sometimes called compassionate use, is an FDA pathway for a patient with a serious or immediately life-threatening disease or condition to get an investigational product outside a clinical trial. FDA lists five conditions, including that no comparable or satisfactory alternative exists and that enrollment in a clinical trial is not possible. Source

Federal Right to Try

The federal Right to Try Act was approved May 30, 2018. It covers a patient diagnosed with a life-threatening disease or condition who has exhausted approved options, cannot join a clinical trial and gives written informed consent. The drug must have completed a Phase 1 trial, not be FDA approved for any use, and be under an active IND with development ongoing. Source

Exosomes

FDA’s public safety notification of December 6, 2019 says: “There are currently no FDA-approved exosome products.” Source

How we describe NP authority

We use the AANP’s three categories. Full practice means nurse practitioners practice under the exclusive licensure authority of the state board of nursing. Reduced practice means state law requires a career-long collaborative agreement, or limits the setting of at least one element of NP practice. Restricted practice means state law requires career-long supervision, delegation or team management by another provider. Source

Every state, DC, Puerto Rico and four provinces.

Open your state. Each one lists who does what, any state law on stem cell or regenerative products, Right to Try, and your boards, with the sources linked.

Alabama: reduced practice for NPs, physician supervision for PAs, no stem cell specific law found, and the Gabe Griffin Right to Try Act for patients with a terminal illness.

Nurse practitioners. Alabama has reduced practice for nurse practitioners, according to the AANP. An Alabama nurse practitioner works under a collaborative practice agreement with an Alabama physician and under written protocols approved by the State Board of Medical Examiners and the Board of Nursing. Source

Physician assistants. Alabama law calls a physician assistant an assistant to physician, licensed by the Board of Medical Examiners. The assistant works under the supervision of a board approved physician. That supervision must be a direct, continuing and close relationship, but it does not require on site supervision. Source

Stem cell and regenerative products. We did not find an Alabama law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Alabama has its own Right to Try law, the Gabe Griffin Right to Try Act (Act 2015-320). It lets a manufacturer offer an investigational drug, biological product or device that has finished phase 1 trials, is not FDA approved for general use and is still in an FDA approved trial to a patient with a terminal illness attested by the patient’s own physician, who has considered all FDA approved options, has a physician’s recommendation and has given written informed consent. The law does not require a manufacturer to offer the product. Source

Boards. Alabama Board of Medical Examiners, Alabama Board of Nursing, Alabama State Board of Chiropractic Examiners, Alabama Board of Physical Therapy.

Training in Alabama. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Alaska: full practice authority for NPs, a written collaborative agreement for PAs outside listed facilities, no stem cell specific law found, and a narrow Right to Try provision that shields physicians from board discipline.

Nurse practitioners. Alaska has full practice authority for nurse practitioners, according to the AANP. State law lets an advanced practice registered nurse diagnose and prescribe under rules set by the Board of Nursing. Source

Physician assistants. Under SB 89, in effect since September 16, 2026, a physician assistant in Alaska practices only under a written collaborative agreement with a physician. The agreement is not needed at certain listed facilities, including federal, tribal, military and veterans’ facilities. The State Medical Board can also allow practice at another facility without one. Source

Stem cell and regenerative products. We did not find an Alaska law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Alaska’s medical practice act has its own Right to Try provision (AS 08.64.367), which protects physicians from board discipline. The State Medical Board may not discipline a physician who gives an investigational drug, biological product or device to sustain the life of a patient with a terminal illness who cannot join a current clinical trial for it, has considered all FDA approved options with the physician, and has given written informed consent. The product must have finished Phase 1 trials, remain in Phase 2 or Phase 3 trials or the new drug application process, and not be FDA approved for general use. Source

Boards. State Medical Board, Alaska Board of Nursing, Board of Chiropractic Examiners, State Physical Therapy & Occupational Therapy Board.

Training in Alaska. Anchorage, Fairbanks.

Alberta: no AANP rating applies, physician assistants work under physician supervision, and Health Canada classes all cell therapies as drugs, while PRP that a practitioner such as a physician or dentist obtains from a patient and gives back to the same patient in a single procedure is regulated provincially. CPSA publishes a PRP guideline for physicians who offer PRP in office and clinic settings.

Nurse practitioners. The AANP practice categories cover US jurisdictions and do not rate Alberta. The College of Registered Nurses of Alberta regulates nurse practitioners. It states that nurse practitioners have the authority to assess a patient and determine a medical diagnosis. They obtain a PracID to prescribe medications and order diagnostic tests. Source

Physician assistants. The College of Physicians and Surgeons of Alberta (CPSA) began regulating physician assistants on April 1, 2021. CPSA states that physician assistants work under the supervision of a physician and are not independent practitioners. The supervising physician remains most responsible for care of the patient. A physician assistant must not perform a restricted activity that the supervising physician is not competent to perform or that is not appropriate to the supervising physician’s scope of practice. Source

Health Canada cell therapy policy. Canada’s federal policy on autologous cell therapy products states that all cell therapies are drugs under the Food and Drugs Act. It states that “advanced” autologous cell therapy products must be licensed for sale and advertising through the market authorization process, except when they are for use in clinical research. Source

Health Canada PRP position (2019). Canada’s federal position, posted July 26, 2019, is that platelet rich plasma (PRP) meets the definition of a drug under the Food and Drugs Act. Its preparation falls under the practice of medicine and dentistry and is regulated at the provincial and territorial level when a practitioner, such as a physician or dentist, obtains it from a patient and gives it back to the same patient in a single procedure. Source

CPSA PRP guideline (2024). The College of Physicians and Surgeons of Alberta (CPSA) publishes a PRP guideline for Alberta licensed physicians who offer PRP in office and clinic settings that are not accredited facilities. It was last updated in October 2024. It states that all health care providers involved in or performing PRP therapy must complete a comprehensive training program that covers all aspects of the procedure. It also states that commercial kits, centrifuges and other specialized medical equipment must be approved by Health Canada. Source

Boards. College of Physicians and Surgeons of Alberta, College of Registered Nurses of Alberta, College of Chiropractors of Alberta, College of Physiotherapists of Alberta.

Training in Alberta (Canada). Edmonton, Calgary.

Arizona: full practice authority for NPs, collaborative practice for PAs with 8,000 clinical hours and Board authorization to work without supervision, supervision agreements for others, no state stem cell therapy notice or consent law found, and a Right to Try law (Proposition 303) with a separate individualized investigational treatment chapter.

Nurse practitioners. Arizona has full practice authority for nurse practitioners, according to the AANP. Source

Physician assistants. Under HB 2043, in effect since December 31, 2023, some Arizona physician assistants practice collaboratively without supervision. This requires at least 8,000 clinical hours and sign-off from the Arizona Regulatory Board of Physician Assistants. Those who practice under supervision need a supervision agreement that sets out their scope of practice and prescribing authority before they start care tasks. Source

Stem cell and regenerative products. We did not find an Arizona law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Arizona has its own Right to Try law, Proposition 303 (2014). It lets a manufacturer offer an investigational drug, biological product or device that has finished phase one trials, is not FDA approved for general use and is still in a clinical trial to eligible patients with a terminal illness. A separate chapter lets a manufacturer in an eligible facility offer an individualized investigational treatment to a patient with a life-threatening disease or condition or a severely debilitating illness. Source

Boards. Arizona Medical Board, Arizona Board of Osteopathic Examiners in Medicine and Surgery, Arizona State Board of Nursing, Arizona Regulatory Board of Physician Assistants, Arizona State Board of Chiropractic Examiners, Arizona Board of Physical Therapy.

Training in Arizona. Phoenix.

Arkansas: reduced practice for NPs with a path to full independent practice, physician supervision for PAs, no stem cell specific law found, and two Right to Try laws (Act 374 of 2015 and Act 201 of 2025).

Nurse practitioners. Arkansas has reduced practice for nurse practitioners, according to the AANP. Under Act 412 of 2021, a nurse practitioner can apply for full independent practice after at least 6,240 hours under a collaborative practice agreement. Once granted, the nurse practitioner can hold prescriptive authority without that agreement. Source

Physician assistants. An Arkansas physician assistant works under an agreement with a supervising physician. Supervision must be continuous, but the physician does not always have to be present. The written agreement is signed by both and updated every year. Source

Stem cell and regenerative products. We did not find an Arkansas law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Arkansas has its own Right to Try law, the Right to Try Act (Act 374 of 2015). It covers patients with a terminal illness and investigational drugs, biological products or devices that have finished phase I trials, are not FDA approved for general use and are still in an FDA trial, and a manufacturer is not required to offer them. Act 201 of 2025 added a separate Right to Try Individualized Investigational Treatment Act for patients with a life-threatening or severely debilitating illness. Source

Boards. Arkansas State Medical Board, Arkansas State Board of Nursing, Arkansas State Board of Chiropractic Examiners, Arkansas State Board of Physical Therapy.

Training in Arkansas. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

British Columbia: no AANP rating applies, physician assistants are licensed by CPSBC to work in hospital emergency departments under physician supervision, and Health Canada classes all cell therapies as drugs, while PRP that a practitioner such as a physician or dentist obtains from a patient and gives back to the same patient in a single procedure is regulated provincially.

Nurse practitioners. The AANP practice categories cover US jurisdictions and do not rate British Columbia. The British Columbia College of Nurses and Midwives (BCCNM) states that nurse practitioners diagnose within their scope of practice. It states that they prescribe medications and order and interpret diagnostic tests. Source

Physician assistants. The College of Physicians and Surgeons of British Columbia (CPSBC) licenses physician assistants. Its bylaws for licensing and regulating them took effect October 25, 2023. CPSBC states that the licence permits physician assistants to work in hospital emergency departments. They must limit their practice to the services in their employment contract with the health authority, as directed and supervised by the attending physician. Source

Health Canada cell therapy policy. Canada’s federal policy on autologous cell therapy products states that all cell therapies are drugs under the Food and Drugs Act. It states that “advanced” autologous cell therapy products must be licensed for sale and advertising through the market authorization process, except when they are for use in clinical research. Source

Health Canada PRP position (2019). Canada’s federal position, posted July 26, 2019, is that platelet rich plasma (PRP) meets the definition of a drug under the Food and Drugs Act. Its preparation falls under the practice of medicine and dentistry and is regulated at the provincial and territorial level when a practitioner, such as a physician or dentist, obtains it from a patient and gives it back to the same patient in a single procedure. Source

Boards. College of Physicians and Surgeons of British Columbia, British Columbia College of Nurses and Midwives, College of Complementary Health Professionals of BC, College of Health and Care Professionals of BC.

Training in British Columbia (Canada). Vancouver.

California: restricted practice for NPs, physician supervision and a practice agreement for PAs, a stem cell notice law (SB 512) for therapies that are not FDA approved, a tissue bank license rule, and a Right to Try law (AB 1668).

Nurse practitioners. California has restricted practice for nurse practitioners, according to the AANP. A nurse practitioner furnishes or orders drugs and devices under standardized procedures or protocols developed with a supervising physician and surgeon. Under Business and Professions Code 2837.103, a nurse practitioner who meets its requirements, including a transition to practice of at least three full time equivalent years or 4,600 hours, may work without standardized procedures in listed settings where one or more physicians and surgeons practice with the nurse practitioner. Source

Physician assistants. California physician assistants work under the supervision of a licensed physician and surgeon. They also work under a practice agreement that meets Business and Professions Code 3502.3. Source

SB 512 (2017), amended by SB 1495 (2018). A licensed practitioner who performs a stem cell therapy that is subject to FDA regulation but is not FDA approved must give patients seeking it a set notice in English, posted where patients see it and at the office entrance and given in writing before the first therapy, each at least 8.5 by 11 inches in 40 point type or larger. Stem cell therapy here means a therapy using HCT/Ps, not counting HCT/Ps that meet 21 CFR 1271.10 or an exception in 21 CFR 1271.15, and the rule does not apply to a practitioner with an FDA investigational new drug approval or device exemption for the HCT/Ps. The licensing board can fine up to $1,000 per violation, but not on a first complaint. Source

Tissue bank license law (Section 1635.1). Every tissue bank operating in California must hold a current state tissue bank license. A physician and surgeon who collects tissue from their own patient or implants tissue into their own patient is exempt, but that exemption does not cover processing or storing the tissue. A separate exemption covers a licensed physician or podiatrist who stores an approved device or biologic HCT/P from a California licensed tissue bank for use only on their own patients, if the practice notifies the state in writing. Source

Right to Try. California has its own Right to Try law, the Right to Try Act (AB 1668), in effect since January 1, 2017. It covers investigational drugs, biological products and devices for a patient with an immediately life-threatening disease or condition. The patient must have considered all FDA approved options, not been accepted into the nearest clinical trial within one week of applying (or the patient’s physician must judge trial participation unreasonable), received recommendations from a primary and a consulting physician, and given written informed consent. Source

Boards. Medical Board of California, Osteopathic Medical Board of California, Board of Registered Nursing, Physician Assistant Board, Board of Chiropractic Examiners, Physical Therapy Board of California.

Training in California. Los Angeles, Riverside, San Francisco, San Diego, Sacramento.

Colorado: full practice authority for NPs, a collaborative agreement for PAs that is a supervisory agreement for newer PAs, no state stem cell therapy notice or consent law found, and a Right to Try law (HB 14-1281) plus an individualized investigational product law (HB 25-1270).

Nurse practitioners. Colorado has full practice authority for nurse practitioners, according to the AANP. The State Board of Nursing can authorize advanced practice registered nurses on the advanced practice registry who meet the law’s requirements to prescribe controlled substances and prescription drugs. Source

Physician assistants. A Colorado physician assistant must have a collaborative agreement with a physician or a physician group. For a physician assistant with fewer than 5,000 practice hours, or fewer than 3,000 hours in a new practice area, that agreement is a supervisory agreement with added requirements. Source

Stem cell and regenerative products. We did not find a Colorado law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Colorado has its own Right to Try law, the Right to Try Act (HB 14-1281). It covers patients with a terminal illness and investigational drugs, biological products and devices that have finished phase one trials, are not FDA approved for general use and are still in an FDA approved trial. HB 25-1270, in effect since May 19, 2025, separately lets a patient with a life-threatening or severely debilitating illness ask a manufacturer for an individualized investigational drug, biological product or device. Source

Boards. Colorado Medical Board, State Board of Nursing, Colorado State Board of Chiropractic Examiners, State Physical Therapy Board.

Training in Colorado. Denver.

Connecticut: full practice authority for NPs after three years and 2,000 hours in collaboration, a written delegation agreement for PAs, no state stem cell therapy notice or consent law found, and a Right to Try law (Public Act 16-214) for patients with a terminal illness.

Nurse practitioners. Connecticut has full practice authority for nurse practitioners, according to the AANP. A newly licensed advanced practice registered nurse must work in collaboration with a Connecticut physician for at least three years and 2,000 hours before practicing alone. Source

Physician assistants. Connecticut physician assistants perform medical functions delegated by a supervising physician, under that physician’s oversight, control and direction. The work follows a written delegation agreement between the supervising physician and the physician assistant. Source

Stem cell and regenerative products. We did not find a Connecticut law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Connecticut has its own Right to Try law, Public Act 16-214, in effect since October 1, 2016. It makes a patient with a terminal illness eligible for an investigational drug, biological product or device that has finished a phase one trial, is not FDA approved for general use and is still in an FDA approved trial. The patient must have considered all FDA approved options, been unable to join a clinical trial within 100 miles or not accepted within one week, have a physician’s recommendation, and have given written informed consent. Source

Boards. Connecticut Medical Examining Board, Board of Examiners for Nursing, State Board of Chiropractic Examiners, Board of Examiners for Physical Therapists.

Training in Connecticut. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Delaware: full practice authority for NPs, a collaborative agreement for physician associates with a path to independent practice authority after more than 6,000 clinical hours, no stem cell specific law found, and a yearly registration rule for tissue banks.

Nurse practitioners. Delaware has full practice authority for nurse practitioners, according to the AANP. The Board of Nursing grants full practice and prescriptive authority when it issues an APRN license, and the former collaborative agreement section of the law was repealed in 2021. Source

Physician assistants. Delaware law uses the title physician associate. Except as the law provides or in a medical emergency, a physician associate may not perform any medical act without a collaborative agreement with a physician. A physician associate with more than 6,000 postgraduate clinical practice hours can apply to the Regulatory Council for Physician Associates for independent practice authority. Source

Tissue bank registration (Title 16, Chapter 28). All sperm banks and tissue banks operating in Delaware must register with the state by May 1 of each year, with a $5,000 fine for failing to register. A tissue bank is any facility or program that procures, furnishes, donates, processes or distributes corneas, bones, organs or other human tissue for injecting, transfusing or transplanting. Donors must be tested for HIV before the tissue is made available for use, except when the attending physician finds a testing delay would put the recipient’s life at risk, and using tissue in violation of the testing rules is a class E felony. Source

Boards. Board of Medical Licensure and Discipline, Delaware Board of Nursing, Board of Chiropractic, Examining Board of Physical Therapists and Athletic Trainers.

Training in Delaware. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

District of Columbia: full practice authority for NPs, physician collaboration for PAs, no stem cell specific law found, and a tissue bank license rule limited to physicians and hospitals.

Nurse practitioners. The District of Columbia has full practice authority for nurse practitioners, according to the AANP. District of Columbia Law 25-191 repealed the code section on APRN collaboration in 2024, and the code lets an advanced practice registered nurse start, monitor and change drug therapies. Source

Physician assistants. In the District of Columbia, physician assistants practice in collaboration with a licensed physician or osteopath. Their work covers medical diagnosis and treatment, prescribing, preventive care and other functions authorized by the Board of Medicine. Source

Tissue bank license law (Code 7-1541.03). No one may operate a tissue bank in the District of Columbia without a license. Licenses go only to licensed or registered physicians or to licensed hospitals. The code defines a tissue bank as a facility for the recovery, screening, testing, processing, storage or distribution of tissue that is accredited by the American Association of Tissue Banks. Source

Boards. Board of Medicine, Board of Nursing, Board of Acupuncture, Chiropractic, and Naturopathic Physicians, Board of Rehabilitative Therapies.

Training in District of Columbia. Washington.

Florida: restricted practice for NPs with a primary care autonomous practice path, physician supervision for PAs, a stem cell therapy law (SB 1768, 2025) that lets physicians perform therapy that is not FDA approved for orthopedics, wound care or pain management under sourcing, notice and consent rules, and a Right to Try law.

Nurse practitioners. Florida has restricted practice for nurse practitioners, according to the AANP. An advanced practice registered nurse works within an established protocol with a supervising physician, unless registered for autonomous practice under section 464.0123. Autonomous practice is limited to primary care and requires, among other things, at least 3,000 clinical practice hours under physician supervision in the prior 5 years. Source

Physician assistants. Florida physician assistants practice under physician supervision. Except in emergencies, supervision requires the licensed physician to be easily available, including by telecommunication, or physically present. A physician can supervise no more than 10 licensed physician assistants at one time. Source

SB 1768 (2025), Stem Cell Therapy. Since July 1, 2025, a Florida physician (MD or DO) may perform stem cell therapy that is not FDA approved if it is within the physician’s scope of practice and related to orthopedics, wound care or pain management; the therapy must use afterbirth placental perinatal stem cells or HCT/Ps that meet the law’s rules, and use of cells or tissues from a fetus or embryo after an abortion is a third degree felony. The cells must be retrieved, manufactured and stored in an FDA registered facility that also holds credentials from one of four named groups and follows current good manufacturing practices under 21 CFR part 1271, and must show live cells after thawing, with a viability report sent to the physician before use. Every advertisement must carry a set notice, and the physician must get a signed consent form stating, among other things, that the therapy is not FDA approved. Source

Right to Try. Florida has its own Right to Try law, the Right to Try Act (2015). It covers a patient with a terminal condition, attested by the patient’s physician and confirmed by a second independent evaluation by a “board-certified” physician in the right specialty, who has considered all FDA approved options and given written informed consent. It applies to investigational drugs, biological products or devices that have finished phase 1 trials, are not FDA approved for general use and are still in an FDA approved trial. Source

Boards. Florida Board of Medicine, Florida Board of Osteopathic Medicine, Florida Board of Nursing, Florida Board of Chiropractic Medicine, Florida Board of Physical Therapy.

Training in Florida. Miami, Tampa, Orlando, Jacksonville.

Georgia: restricted practice for NPs, physician supervision for PAs, a 2026 stem cell law (HB 1275) with consent, sourcing and advertising notice rules for human stem cell therapy that is not FDA approved, the Hope for Georgia Patients Act for individualized investigational treatment, and a Right to Try law.

Nurse practitioners. Georgia has restricted practice for nurse practitioners, according to the AANP. An APRN works under a nurse protocol agreement with a delegating physician, who files it with the Georgia Composite Medical Board. Since May 25, 2026, a delegating physician can have protocol agreements or job descriptions with no more than the combined equivalent of eight APRNs or physician assistants at one time. Source

Physician assistants. Georgia physician assistants work under physician supervision. The responsible physician must get Board approval before delegating tasks, and a job description signed by the primary supervising physician sets the physician assistant’s activities. Since May 25, 2026, a physician can supervise no more than the combined equivalent of eight APRNs or physician assistants at one time. Source

HB 1275 (2026), human stem cell therapy. Since July 1, 2026, a physician, or a physician assistant or nurse practitioner the physician designates, may perform human stem cell therapy that is not FDA approved if it is within the provider’s scope of practice and the patient is advised and signs a consent form. The cells must come from a facility registered with the FDA or one accredited by a named group, and every advertisement must carry a set notice that the therapies are not FDA approved. The consent form must state the nature of the procedure, that it is not FDA approved, and what is expected from it, and the law excludes cells or tissues from an aborted fetus or embryo. Source

SB 72 (2025), Hope for Georgia Patients Act. This law lets a manufacturer or eligible facility make an individualized investigational treatment available to an eligible patient, and its definition includes products derived from human perinatal tissues, cells and secreted factors not obtained from an abortion. It requires written informed consent. The Georgia Composite Medical Board cannot sanction a physician solely for recommending or providing such a treatment under the law. Source

Right to Try. Georgia has its own Right to Try law, the Georgia Right to Try Act (HB 34, 2016). It lets a patient with a terminal illness access an investigational drug, biological product or device that has finished Phase I of an FDA approved trial, if a physician documents the illness, the approved options considered, a physician recommendation and written informed consent. SB 72 (2025) added a separate article for individualized investigational treatments made in an eligible facility for life-threatening or severely debilitating illnesses. Source

Boards. Georgia Composite Medical Board, Georgia Board of Nursing, Georgia Board of Chiropractic Examiners, Georgia State Board of Physical Therapy.

Training in Georgia. Atlanta.

Hawaii: full practice authority for NPs, physician supervision for PAs at a degree set by the Hawaii Medical Board, and no stem cell specific law found.

Nurse practitioners. Hawaii has full practice authority for nurse practitioners, according to the AANP. Hawaii law defines the advanced practice registered nurse scope to include advanced assessment and the diagnosis, prescription, selection and administration of therapeutic measures, including controlled substances, within the nurse’s role and specialty. Source

Physician assistants. Hawaii physician assistants practice medicine under the supervision of a physician, osteopathic physician or group of physicians, and are licensed by the Hawaii Medical Board, which sets the degree of supervision. The law sets medical record review duties for the supervising physician, with more review during a physician assistant’s first year of practice. Source

Stem cell and regenerative products. We did not find a Hawaii law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Boards. Hawaii Medical Board, Board of Nursing, Hawaii Board of Chiropractic, Board of Physical Therapy.

Training in Hawaii. Honolulu.

Idaho: full practice authority for NPs, physician collaboration for PAs, no state stem cell therapy notice or consent law found, and a Right to Try law (HB 481, 2016) for patients with a terminal illness.

Nurse practitioners. Idaho has full practice authority for nurse practitioners, according to the AANP. Idaho law authorizes an advanced practice registered nurse to perform advanced nursing practice as provided by the Board of Nursing, and says the nurse collaborates with other professionals in providing care. Source

Physician assistants. Idaho physician assistants are licensed by the Board of Medicine and must, at a minimum, collaborate with one or more Idaho licensed physicians. The degree of collaboration is set by facility bylaws or procedures, or by a written collaborative practice agreement in other practices. A physician assistant with at least two years of licensure can own a practice if each physician assistant has a collaborative practice agreement with a physician. Source

Stem cell and regenerative products. We did not find an Idaho law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Idaho has its own Right to Try law, the Right to Try Act (House Bill 481, 2016). A patient with a terminal illness can request, and a manufacturer can offer under the supervision of the patient’s physician, an investigational drug, biological product or device that has finished phase 1 of a clinical trial and is still in an FDA approved trial. Written informed consent is required, insurers and government agencies do not have to cover it, and a licensing board cannot act against a provider’s license based solely on recommendations made under the law. Source

Boards. State Board of Medicine, Board of Nursing for the State of Idaho, State Board of Chiropractic Physicians, Idaho Physical Therapy Licensure Board.

Training in Idaho. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Illinois: reduced practice for NPs, a written collaborative agreement for PAs outside hospitals, hospital affiliates and ambulatory surgical treatment centers, a 2019 IDFPR warning that stem cell injections are for MDs and DOs, and a medspa memo that requires a physician to perform or delegate medical procedures.

Nurse practitioners. Illinois has reduced practice for nurse practitioners, according to the AANP. The Illinois Department of Financial and Professional Regulation (IDFPR) states that APRNs who hold full practice authority under 225 ILCS 65/65-43 can practice without a written collaborative agreement in all practice settings consistent with their national certification. Source

Physician assistants. Illinois physician assistants practice under a written collaborative agreement with a collaborating physician, except in hospitals, hospital affiliates or ambulatory surgical treatment centers under Section 7.7 of the Physician Assistant Practice Act. The IDFPR notice form states that a collaborating physician can collaborate with up to 7 full-time equivalent physician assistants. Source

IDFPR stem cell consumer warning (2019). In a May 31, 2019 consumer warning, IDFPR stated that under the Medical Practice Act, stem cell injections can only be ordered and given by physicians licensed to practice medicine in all its branches (MDs and DOs). It said the Act lets an APRN or physician assistant give injectables in certain circumstances, and that providers must not make claims for their products that are untrue and lack scientific support. IDFPR urged consumers to avoid stem cell treatments given by chiropractors or others not licensed to provide them without collaboration with an MD, DO or other authorized provider. Source

State medical spa memo (2025). A joint state agency memo on medical spas, updated October 30, 2025, lists platelet rich plasma among procedures performed in medspas. It states that medical procedures at a medspa must be performed by a licensed physician, or by a person the physician delegates to who is properly trained and supervised by the physician, within a physician-patient relationship. Source

Boards. Illinois State Medical Board, Board of Nursing, Physical Therapy Licensing and Disciplinary Board.

Training in Illinois. Chicago.

Indiana: reduced practice for NPs, a written collaborative agreement for PAs, no state stem cell therapy notice or consent law found, an HCT/P law that classes their use as a service rather than a sale, and Right to Try and experimental treatment provisions with written disclosure rules.

Nurse practitioners. Indiana has reduced practice for nurse practitioners, according to the AANP. An advanced practice registered nurse, other than a nurse anesthetist, works in collaboration with a licensed practitioner as shown by a practice agreement, or under privileges granted by a hospital governing board. Source

Physician assistants. Indiana physician assistants must work in a dependent practice with a collaborating physician under a written collaborative agreement. The agreement lists the delegated tasks, emergency procedures and prescribing protocol, and the physician submits it to the board. Source

HCT/P service law (IC 16-41-12-11). Indiana law classes the procurement, processing, distribution or use of HCT/Ps by a bank, storage facility or hospital, and their injection or transplantation by a hospital, physician or surgeon, as a service and not the sale of a product. So these services do not give rise to an implied warranty of merchantability or fitness or to strict liability in tort. HCT/Ps has the meaning in the federal rule at 21 CFR 1271.3(d). Source

Right to Try. Indiana has its own Right to Try law (P.L.2-2015), which lets a manufacturer make an investigational drug, biological product or device that has finished Phase I of an FDA approved trial available to a qualified patient, and a 2025 law (IC 16-42-26.5) covers individualized investigational treatments made for one patient from that patient’s genetic profile. A related provision (IC 25-22.5-1-2.1) allows a consenting patient to receive experimental or nonconventional treatment if a licensed physician has personally examined the patient and agrees to provide it, the law’s risk conditions are met, and the physician gives a signed written statement and oral explanation disclosing that it is experimental or nonconventional, any lack of FDA approval, its material risks, and its expected frequency and duration. For care outside a hospital, the law directs the Medical Licensing Board to develop protocols, and a physician who fails to follow them is subject to board discipline. Source

Boards. Medical Licensing Board of Indiana, Indiana State Board of Nursing, Indiana Physician Assistant Committee, Indiana Board of Chiropractic Examiners, Indiana Board of Physical Therapy.

Training in Indiana. Indianapolis.

Iowa: full practice authority for NPs, practice level collaboration for physician assistants (now physician associates), no state stem cell therapy notice or consent law found, and a Right to Try Act that since 2025 also covers individualized investigational treatment.

Nurse practitioners. Iowa has full practice authority for nurse practitioners, according to the AANP. Iowa law uses the title advanced registered nurse practitioner (ARNP), a registered nurse licensed by the Board of Nursing as an ARNP. Source

Physician assistants. Iowa physician assistants, retitled physician associates by a 2026 act that does not change their scope, can provide medical services they are prepared and competent to perform, with the degree of collaboration set at the practice level. A physician assistant in independent practice must be supervised by a physician for the first two years, unless they have already practiced at least two years under a supervising physician or in collaboration. Source

Stem cell and regenerative products. We did not find an Iowa law that requires a patient notice or consent form for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Iowa has its own Right to Try law, the Right to Try Act (Iowa Code chapter 144E). A patient with a terminal illness can request, and a manufacturer can offer, an investigational drug, biological product or device that has finished phase 1 of an FDA approved trial, with physician documentation and written informed consent. Since 2025, a patient with a life-threatening or severely debilitating illness can also seek an individualized investigational treatment made from the patient’s genetic profile through an eligible facility, and the Board of Medicine cannot act against a physician’s license based solely on recommendations made under the law. Source

Boards. Iowa Board of Medicine, Iowa Board of Nursing, Iowa Board of Physician Associates, Iowa Board of Chiropractic, Iowa Board of Physical and Occupational Therapy.

Training in Iowa. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Kansas: full practice authority for NPs, physician supervision for PAs, and no state stem cell therapy notice or consent law found.

Nurse practitioners. Kansas has full practice authority for nurse practitioners, according to the AANP. Under Kansas law, as amended in 2022, an advanced practice registered nurse can prescribe durable medical equipment and prescribe, procure and administer any drug consistent with their role and population focus, except a drug intended to cause an abortion, with controlled substances handled under the uniform controlled substances act. Source

Physician assistants. Kansas physician assistants practice in a dependent role with a supervising physician. They perform acts that are the practice of medicine only under a physician’s direction and supervision, to the extent the responsible physician authorizes and board rules allow. They can prescribe drugs under a written agreement authorized by the supervising physician. Source

Stem cell and regenerative products. We did not find a Kansas law that requires a patient notice or consent form for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Boards. Kansas State Board of Nursing.

Training in Kansas. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Kentucky: reduced practice for NPs with collaborative prescribing agreements, a signed supervision agreement for PAs, no stem cell specific law found, and a Right to Try law (2017) for patients with a terminal illness.

Nurse practitioners. Kentucky has reduced practice for nurse practitioners, according to the AANP. An advanced practice registered nurse needs a written collaborative agreement with a Kentucky physician before prescribing nonscheduled legend drugs (CAPA-NS), and a standardized one before prescribing Schedule II to V controlled substances (CAPA-CS). After four years of prescribing, an APRN can drop the CAPA-NS by notifying the Board of Nursing, and can be exempt from the CAPA-CS only after the Board of Nursing reviews the license and confirms in writing that it is in good standing. Source

Physician assistants. Kentucky physician assistants work under a supervising physician approved by the Kentucky Board of Medical Licensure. A physician assistant cannot provide any medical service until a signed supervision agreement is in effect that sets the scope of services and the level and method of supervision. A physician can supervise no more than four physician assistants at one time. Source

Stem cell and regenerative products. We did not find a Kentucky law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Kentucky has its own Right to Try law (KRS 217.5401 to 217.5408), in effect since June 29, 2017. It lets a manufacturer make an investigational drug, biological product or device that has finished Phase I of a clinical trial and is still in an FDA approved trial available to a patient with a terminal illness. The patient’s own provider (a licensed physician, APRN or physician assistant) must attest to the illness, recommend the product and document eligibility, the patient must give written informed consent, and the manufacturer is not required to provide it. Source

Boards. Kentucky Board of Medical Licensure, Kentucky Board of Nursing, Kentucky State Board of Chiropractic Examiners, Kentucky Board of Physical Therapy.

Training in Kentucky. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Louisiana: reduced practice for NPs, physician supervision for PAs, a 2013 medical board statement that limits the use of stem cell products that are not FDA approved, a Right to Try law, and the 2024 Hope for Louisiana Patients Law, which lets a manufacturer in an eligible facility offer individualized investigational treatments, a term that includes perinatal tissue products, to patients with a life-threatening or severely debilitating illness.

Nurse practitioners. Louisiana is a reduced practice state for nurse practitioners, according to AANP. Here, an APRN’s acts of medical diagnosis and prescription must follow a collaborative practice agreement with one or more physicians or dentists, and the APRN must file that agreement with the Louisiana State Board of Nursing and receive approval. Source

Physician assistants. Louisiana physician assistants practice under the supervision of a physician approved by the Louisiana State Board of Medical Examiners, who takes on legal liability for the PA’s services. The level and method of supervision is set by the physician and the PA, documented, and reviewed each year. A PA may not practice without supervision except in life-threatening emergencies and disaster relief. Source

Medical board statement on non-FDA approved stem cell products (2013). The Louisiana State Board of Medical Examiners says stem cell products should not be used unless the FDA has approved the product, approved it as an investigational new drug with the patient enrolled in an FDA approved trial, issued a permissive use disclaimer, or exempted it from approval. Physicians should charge only for FDA approved stem cell products, and using unapproved or unproven stem cell products may lead to discipline for unprofessional conduct. The statement covers cells such as adipose derived stem cells, and excludes blood products such as platelets and plasma and tissues such as skin and bone. Source

Hope for Louisiana Patients Law (2024). The Hope for Louisiana Patients Law, effective August 1, 2024, lets a manufacturer within an eligible facility make individualized investigational treatments available to patients with a life-threatening or severely debilitating illness. Its definition of individualized investigational treatment includes a drug, biological product or device made from human perinatal tissues, cells and secreted factors not obtained from an abortion. It excludes products made from human embryonic stem cells or cell lines, or from tissues or cells from an abortion. Source

Right to Try. Louisiana has its own Right to Try law. It lets a manufacturer make an investigational drug, biological product or device available to a patient with a terminal illness who has no comparable FDA approved option, has a physician’s prescription or recommendation, and has given written consent, and insurers are not required to cover it. Separately, the Hope for Louisiana Patients Law, effective August 1, 2024, lets a manufacturer within an eligible facility make individualized investigational treatments available to patients with a life-threatening or severely debilitating illness. Source

Boards. Louisiana State Board of Medical Examiners, Louisiana State Board of Nursing, Louisiana State Board of Chiropractic Examiners, Louisiana Physical Therapy Board.

Training in Louisiana. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Maine: full practice authority for NPs, a collaborative agreement for newer physician associates, and a Right to Try law for patients with a terminal illness; no state stem cell law found.

Nurse practitioners. Maine is a full practice authority state for nurse practitioners, according to AANP. Maine law requires a nurse practitioner who qualifies as an APRN to practice for at least 24 months under the supervision of a licensed physician or a supervising nurse practitioner, or to be employed by a clinic or hospital whose medical director is a licensed physician. Source

Physician assistants. Maine law now uses the title physician associate. A physician associate with less than 4,000 hours of clinical practice documented to the board must work under a collaborative agreement with an active physician, or under the credentialing, privileges and scope of practice agreement of a group practice or facility. A physician associate with more than 4,000 hours who is the principal clinical provider in a practice without a physician partner must have a practice agreement with an active physician. Source

Stem cell and regenerative products. We did not find a Maine law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Maine has its own Right to Try law. It lets a manufacturer make an investigational drug, biological product or device that has completed Phase I and remains under investigation in an FDA approved trial available to a patient with a terminal illness for which no standard treatment is effective, as attested by the patient’s physician. The patient must have considered all FDA approved options, not been accepted into a clinical trial within one week of applying, have that physician’s recommendation, and give written, informed consent. Source

Boards. Maine Board of Licensure in Medicine, Maine Board of Osteopathic Licensure, Maine State Board of Nursing, Board of Chiropractic Licensure, Board of Physical Therapy.

Training in Maine. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Maryland: full practice authority for NPs, a collaboration agreement for PAs, and a Right to Try law that covers individualized investigational treatments; no state stem cell therapy notice or consent law found.

Nurse practitioners. Maryland is a full practice authority state for nurse practitioners, according to AANP. An applicant for initial nurse practitioner certification who has not held that certification from any board of nursing must name a mentor who will consult and collaborate with the applicant for 18 months. Source

Physician assistants. Maryland physician assistants practice under a collaboration agreement developed with a physician or group of physicians. A physician assistant may practice only after notifying the Maryland Board of Physicians of the executed collaboration agreement. Source

Stem cell and regenerative products. We did not find a Maryland law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Maryland has its own Right to Try law, passed in 2017 and amended in 2024. As amended, it covers individualized investigational treatments: a drug, biological product or device unique to and made only for one person based on that person’s genetic profile. A manufacturer operating within an eligible facility may provide one to a patient with a life-threatening or severely debilitating illness who has given informed consent, at no charge or at the patient’s cost. Source

Boards. Maryland Board of Physicians, Maryland Board of Nursing, Maryland State Board of Chiropractic Examiners, Maryland Board of Physical Therapy Examiners.

Training in Maryland. Baltimore.

Massachusetts: full practice authority for NPs after 2 years of supervised practice, continuous physician supervision for PAs, and no state stem cell therapy notice or consent law found.

Nurse practitioners. Massachusetts is a full practice authority state for nurse practitioners, according to AANP. A nurse practitioner has independent authority to prescribe and to order tests and therapeutics after at least 2 years of supervised practice; before that, prescribing follows guidelines agreed with a supervising nurse practitioner who has independent practice authority or a supervising physician. Source

Physician assistants. Massachusetts physician assistants perform medical services under the supervision of a registered physician. Supervision must be continuous but does not require the supervising physician to be present in person. Source

Stem cell and regenerative products. We did not find a Massachusetts law that requires a patient notice or consent form for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Boards. Board of Registration in Medicine, Board of Registration in Nursing, Board of Registration of Physician Assistants, Board of Registration of Chiropractors, Board of Allied Health Professions.

Training in Massachusetts. Boston.

Michigan: restricted practice for NPs, a practice agreement for PAs, and a Right to Try law for patients with an advanced illness.

Nurse practitioners. Michigan is a restricted practice state for nurse practitioners, according to AANP. Michigan law lets an APRN prescribe nonscheduled prescription drugs, and schedule 2 to 5 controlled substances only as a delegated act of a physician. Source

Physician assistants. Michigan law bars a physician’s assistant from practicing except under the terms of a practice agreement with a participating physician. The agreement must include a process for communication, availability and decision making, a protocol for designating an alternative physician, and the signatures of both parties. Source

Stem cell and regenerative products. Check with the Michigan Board of Medicine or the Michigan Board of Osteopathic Medicine and Surgery for any Michigan rule on stem cell or regenerative products. Federal FDA rules apply either way.

Right to Try. Michigan has its own Right to Try law, in effect since October 17, 2014. It covers a patient with an advanced illness, attested by the patient’s physician, who has considered all FDA approved options, has a physician’s recommendation and has given written, informed consent. The drug, biological product or device must have completed phase 1 and remain under investigation in an FDA approved clinical trial, and a plan, third party administrator or government agency is not required to cover the cost. Source

Boards. Michigan Board of Medicine, Michigan Board of Osteopathic Medicine and Surgery, Michigan Board of Nursing, Michigan Task Force on Physician’s Assistant, Michigan Board of Chiropractic, Michigan Board of Physical Therapy.

Training in Michigan. Detroit.

Minnesota: full practice authority for NPs after 2,080 collaborative hours, a practice agreement for PAs, and a Right to Try law for patients with a terminal illness.

Nurse practitioners. Minnesota is a full practice authority state for nurse practitioners, according to AANP. Minnesota law requires a nurse practitioner or clinical nurse specialist who qualifies for APRN licensure to practice at least 2,080 hours within a collaborative agreement in a hospital or integrated clinical setting where APRNs and physicians work together. Source

Physician assistants. Minnesota physician assistants practice medicine only under an established practice agreement. The agreement is kept at the practice level and must be reviewed each year by a licensed physician in the same clinic, hospital, system or other facility. Source

Stem cell and regenerative products. Check with the Minnesota Board of Medical Practice for any Minnesota rule on stem cell or regenerative products. Federal FDA rules apply either way.

Right to Try. Minnesota has its own Right to Try law. A manufacturer may, but does not have to, make available an investigational drug, biological product or device that has completed phase 1, is not FDA approved, and is under investigation in an FDA clinical trial. A physician must document in writing that the patient has a terminal illness, has considered all FDA approved options, has a physician’s prescription or recommendation, and has given written informed consent. Source

Boards. Minnesota Board of Medical Practice, Minnesota Board of Nursing, Minnesota Board of Chiropractic Examiners, Minnesota State Board of Physical Therapy.

Training in Minnesota. Saint Paul.

Mississippi: reduced practice for NPs, physician supervision for PAs, and SB 2830 (2020), which added adult autologous mesenchymal stem cells that have completed phase one of a clinical trial and remain under investigation in one to the state Right-to-Try Act.

Nurse practitioners. Mississippi is a reduced practice state for nurse practitioners, according to AANP. Mississippi State Board of Medical Licensure rules describe NP collaboration with a physician under a protocol or collaborative agreement, and the physician must report the collaboration to the Board before patient care begins under the protocol. Source

Physician assistants. Mississippi State Board of Medical Licensure rules say physician assistants practice medicine with physician supervision and may provide medical services delegated by the supervising physician. PAs are considered agents of their supervising physicians. Source

SB 2830 (2020). SB 2830 amended Mississippi’s Right-to-Try Act to add patients with a traumatic injury and to include adult autologous mesenchymal stem cells. It covers a patient with a debilitating disability, traumatic injury, terminal illness or life-threatening illness that has not responded to currently approved products or cannot be addressed by them, who has considered approved options and relevant in-state clinical trials, has a physician’s prescription or recommendation, and has given written informed consent. The stem cell, drug, biological product or device must have completed phase one of a clinical trial, not be FDA approved for general use, and remain under investigation in a clinical trial. Source

Right to Try. Mississippi has its own Right to Try law, effective July 1, 2015. It lets licensed physicians prescribe or recommend certain investigational drugs, biological products or devices to eligible patients. A 2016 amendment expanded the patients eligible and gave tort immunity to hospitals where these products are used or purchased, and a 2020 amendment added traumatic injury and adult autologous mesenchymal stem cells. Source

Boards. Mississippi State Board of Medical Licensure, Mississippi Board of Nursing, Mississippi Board of Chiropractic Examiners, Mississippi State Board of Physical Therapy.

Training in Mississippi. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Missouri: restricted practice for NPs, physician collaboration for PAs, and a Right to Try law for patients with a terminal illness; no state stem cell therapy notice or consent law found.

Nurse practitioners. Missouri is a restricted practice state for nurse practitioners, according to AANP. Missouri law lets a physician enter collaborative practice arrangements with registered professional nurses in the form of written agreements, jointly agreed upon protocols or standing orders. Source

Physician assistants. Missouri law bars a physician assistant from practicing without physician collaboration, or where the collaborating physician is not immediately available for consultation, assistance and intervention, except as the statute provides and in an emergency. PA prescribing must be under a collaborative practice arrangement. Source

Stem cell and regenerative products. We did not find a Missouri law that requires a patient notice or consent form for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Missouri has its own Right to Try law, effective August 28, 2014. It lets a manufacturer make an investigational drug, biological product or device that has completed phase one, is not FDA approved for general use and is still in a clinical trial available to a patient with a terminal illness who has a physician’s prescription or recommendation and has given written informed consent. Schedule I controlled substances are excluded, and no state agency or board may act against a physician’s license based solely on recommending such a product. Source

Boards. Missouri Board of Registration for the Healing Arts, Missouri State Board of Nursing, Missouri Board of Chiropractic Examiners, Advisory Commission for Physical Therapists (Missouri Board of Registration for the Healing Arts).

Training in Missouri. St. Louis, Kansas City.

Montana: full practice authority for NPs, a collaborative agreement for PAs with fewer than 8,000 hours, and SB 535 (2025), which licenses experimental treatment centers and extends the Right to Try Act to experimental treatments that have completed phase 1 but are not FDA approved for general use.

Nurse practitioners. Montana is a full practice authority state for nurse practitioners, according to AANP. Source

Physician assistants. A Montana physician assistant with fewer than 8,000 hours of postgraduate clinical experience must practice under a collaborative agreement with one or more collaborating providers, meaning a licensed physician or a physician assistant with 8,000 or more hours, and follow written practice-level policies. A physician assistant who actively practiced 8,000 hours before October 1, 2023 is exempt. Source

SB 535 (2025). SB 535 requires a state license to operate an experimental treatment center, with a $10,000 application fee and a $5,000 annual renewal, and amends the Right to Try Act to cover experimental treatments. An experimental treatment uses an investigational drug, biological product, device or other treatment that has completed phase 1 of a clinical trial but is not FDA approved for general use, and that either remains in an FDA approved clinical trial or has a documented safety record from a qualified medical institution as defined by department rule. The law is not limited to stem cells. Source

Experimental treatment center rules (2026). Montana’s DPHHS adopted 25 new rules for experimental treatment centers, effective July 25, 2026. A center must have a medical director with a current physician license in good standing with the Montana Board of Medical Examiners and must establish or contract with an experimental treatment review board. A center must report serious adverse events to the department within five days. Source

Right to Try. Montana has its own Right to Try law, amended in 2023 and 2025. A manufacturer, provider or facility may make an experimental treatment available on a patient’s request, free or under payment arrangements, and none is required to. The patient must have evaluated FDA approved options, received a recommendation for the experimental treatment from the patient’s own provider, given informed consent, and received documentation of eligibility from that provider. Source

Boards. Board of Medical Examiners, Board of Nursing, Board of Chiropractors, Board of Physical, Rehabilitative, and Developmental Health Care Professionals.

Training in Montana. Bozeman.

Nebraska: full practice authority for NPs, and LB 752 (2022), which requires written informed consent telling patients that stem-cell-based therapy is not FDA approved.

Nurse practitioners. Nebraska is a full practice authority state for nurse practitioners, according to AANP. A nurse practitioner license applicant must show 2,000 hours of practice as a nurse practitioner under a transition-to-practice agreement, a collaborative agreement, an integrated practice agreement, independent practice, or a combination of these. Source

Physician assistants. Nebraska physician assistants perform medical services delegated by and under the supervision of a licensed physician, who must be a party to a collaborative agreement with the PA. Supervision must be continuous but does not require physical presence. A physician may supervise no more than four PAs at a time unless the board grants a waiver. Source

LB 752 (2022). Any practitioner licensed or certified under the Uniform Credentialing Act who performs stem-cell-based therapy must tell each patient seeking it, through informed written consent, that it is not FDA approved. The signed consent must confirm that the practitioner explained the treatment, that it has not received FDA approval, including for experimental use, and that the patient understands this. The rule does not apply to FDA approved products or to therapy for which the practitioner obtained FDA investigational new drug or device approval, and failing to comply is a ground for discipline. Source

Right to Try. Nebraska has its own Right to Try law, the Investigational Drug Use Act of 2018. A manufacturer may, but is not required to, make an investigational drug, biological product or device available to a patient with an advanced illness attested by the patient’s physician. The patient must have considered FDA approved options, have that physician’s recommendation, give written, informed consent, have documentation of eligibility, and not be an inpatient in a licensed hospital. Source

Boards. Board of Medicine and Surgery, Board of Nursing, Board of Chiropractic, Board of Physical Therapy.

Training in Nebraska. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Nevada: full practice authority for NPs, and 2009 statutes that let a licensed person administer nonembryonic cells, including stem cells, within that license while stating they do not settle federal status.

Nurse practitioners. Nevada is a full practice authority state for nurse practitioners, according to AANP. Nevada law lets an APRN engage in selected medical diagnosis and treatment and prescribe, but a schedule II controlled substance requires at least 2 years or 2,000 hours of clinical experience or a protocol approved by a collaborating physician. Source

Physician assistants. Nevada physician assistants perform the medical services that the supervising physician authorizes. PAs are licensed by the Board of Medical Examiners, and a PA may also hold a simultaneous license from the State Board of Osteopathic Medicine. Source

Nonembryonic cells law, NRS 629.300 to 629.390 (2009). Nevada law defines nonembryonic cells as autologous or allogeneic cells, including stem cells and immune cells, not obtained directly from human embryos, and allows a cell or tissue bank that stores them to operate in the state. A licensed person may administer these cells if the mode of delivery is permitted under that person’s license, and state and local agencies, including professional boards, may not regulate or discipline these authorized activities, though licensing boards still regulate licensees and the procedures used. The statutes say they do not indicate the status of these activities under federal law. Source

Right to Try. Nevada has its own Right to Try law, passed in 2015 and amended in 2023. A manufacturer may provide an investigational drug, biological product or device that has completed Phase 1, is not FDA approved and is in an FDA approved clinical trial, after a physician has prescribed or recommended it, discussed FDA approved options and obtained informed written consent. Through June 30, 2027 it covers life-threatening or severely debilitating conditions and individualized investigational treatments, and from July 1, 2027 it covers terminal conditions only. Source

Boards. Nevada State Board of Medical Examiners, Nevada State Board of Osteopathic Medicine, Nevada State Board of Nursing, Chiropractic Physicians’ Board of Nevada, Nevada Physical Therapy Board.

Training in Nevada. Las Vegas.

New Hampshire: full practice authority for NPs, a collaboration agreement for some physician associates, and a Right to Try law for eligible patients; no state stem cell law found.

Nurse practitioners. New Hampshire is a full practice authority state for nurse practitioners, according to AANP. The Nurse Practice Act gives an APRN plenary authority to prescribe controlled and non-controlled drugs within the APRN’s scope of practice. Source

Physician assistants. New Hampshire calls PAs physician associates, licensed by the Board of Medicine. A physician associate with fewer than 8,000 post-graduate clinical practice hours who practices without at least one New Hampshire licensed physician in the group, practice or system must have a written collaboration agreement with a New Hampshire licensed physician in a similar area of medicine. Until January 1, 2027, a physician associate with more than 8,000 hours in such a setting applies to the Board of Medicine for a waiver of that agreement. Source

Stem cell and regenerative products. We did not find a New Hampshire law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. New Hampshire has its own Right to Try law. It lets a manufacturer make an investigational drug, biologic or device that has completed phase one, is not FDA approved for general use and remains under investigation in a clinical trial available to eligible patients, free or at the cost of manufacture, and the manufacturer is not required to provide it. Since January 1, 2026 the law also covers telehealth prescreening and remote signing of consent. Source

Boards. New Hampshire Board of Medicine, New Hampshire Board of Nursing, New Hampshire Board of Chiropractic Examiners, New Hampshire Physical Therapy Governing Board.

Training in New Hampshire. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

New Jersey: reduced practice for NPs, with joint protocols still required for advanced practice nurses in elective aesthetic or cosmetic services, physician supervision for PAs, and no state stem cell law found.

Nurse practitioners. New Jersey is a reduced practice state for nurse practitioners, according to AANP. A 2026 law lets an advanced practice nurse in a listed population focus with more than 5,000 hours who provides primary or behavioral care practice without a joint protocol, but not one who provides general obstetrics or elective aesthetic or cosmetic services; other advanced practice nurses prescribe and order under joint protocols with a collaborating physician. Source

Physician assistants. New Jersey physician assistants must practice under physician supervision and have a signed delegation agreement with the supervising physician. A temporary emergency waiver of these requirements ran through April 2, 2026. Source

Stem cell and regenerative products. We did not find a New Jersey law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Boards. New Jersey State Board of Medical Examiners, New Jersey Board of Nursing, New Jersey State Board of Chiropractic Examiners, New Jersey State Board of Physical Therapy Examiners.

Training in New Jersey. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

New Mexico: full practice authority for NPs, supervision or collaboration for PAs under Medical Board rules, and no state stem cell law found.

Nurse practitioners. New Mexico is a full practice authority state for nurse practitioners, according to AANP. Board of Nursing rules say the nurse practitioner makes independent decisions about the client’s care needs and in carrying out care regimens. Source

Physician assistants. New Mexico Medical Board rules cover physician assistants who practice under a supervising physician and physician assistants who practice in collaboration with a physician. Collaborative licensure requires, among other things, practicing primary care and three years of clinical practice as a PA with supervision by a licensed physician. Source

Stem cell and regenerative products. We did not find a New Mexico law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Boards. New Mexico Medical Board, New Mexico Board of Nursing, New Mexico Chiropractic Board, New Mexico Physical Therapy Board.

Training in New Mexico. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

New York: full practice authority for NPs after 3,600 hours, physician supervision for PAs, and tissue bank licensing that covers stem cells and requires FDA documentation before umbilical cord tissue can be distributed or transplanted.

Nurse practitioners. New York is a full practice authority state for nurse practitioners, according to AANP. An NP must practice under written practice protocols and a written practice agreement with a collaborating physician until the NP has more than 3,600 hours of practice; after that, Education Law 6902 removes those requirements under a provision marked effective until July 1, 2030. Source

Physician assistants. In New York a physician assistant may perform medical services only under the supervision of a physician and only within the supervising physician’s scope of practice. Supervision must be continuous but does not require the physician’s physical presence, and a physician may supervise no more than six PAs in private practice at one time. Source

Tissue bank licensing (Article 43-B and 10 NYCRR Part 52). New York requires a state tissue bank license for all tissue banking activities, including collection, processing, storage and distribution, and its rules cover tissues including stem cells. Under state guidance, a physician’s practice that stores human tissue onsite more than 24 hours before use needs a tissue bank license unless its clinical use is limited to sterilized products, while a practice that receives tissue just in time and transplants or returns it within 24 hours without removing it from the transport packaging does not. All tissue distributed in New York must come from a New York licensed tissue bank unless the product has been exempted. Source

Birth tissue distribution policy (2022). Since January 21, 2022, distributing most HCT/Ps to New York and using them clinically in New York requires a state tissue bank license. A tissue bank, including a transplantation facility, may not distribute or transplant umbilical cord tissue in New York without a license that lists umbilical cord, and the state will not approve one without FDA documentation such as FDA approval, an IND in effect, or an FDA determination that the product is regulated solely under section 361. Amniotic membrane products in formats other than a sheet of tissue need the same FDA documentation. Source

Boards. New York State Board for Medicine (New York State Education Department, Office of the Professions), New York State Board for Nursing (New York State Education Department, Office of the Professions), New York State Board for Chiropractic (New York State Education Department, Office of the Professions), New York State Board for Physical Therapy (New York State Education Department, Office of the Professions).

Training in New York. New York.

North Carolina: restricted practice for NPs, and a 2019 law that allows an adult stem cell treatment under investigation in a clinical trial and not yet FDA approved only through a physician certified and overseen by a medical school review board.

Nurse practitioners. North Carolina is a restricted practice state for nurse practitioners, according to AANP. NPs work under a collaborative practice agreement signed with a primary supervising physician, and state law conditions NP prescribing on written instructions and a periodic review policy from the supervising physician. Source

Physician assistants. North Carolina physician assistants practice under a supervising physician unless registered for team-based practice, which took effect June 30, 2026. A team-based PA must practice in a team-based setting and have more than 4,000 hours of clinical practice and more than 1,000 hours in the specialty, and collaborates, consults with or refers to the care team. Perioperative surgical or anesthesia-related services still require physician supervision. Source

Investigational Adult Stem Cell Treatments, Session Law 2019-70 (2019). A patient with a severe chronic disease or terminal illness, attested by a physician, who has considered FDA approved options and gives written informed consent may access an investigational adult stem cell treatment that is under investigation in a clinical trial and not yet FDA approved. The treatment must be given directly by a physician under the certification and oversight of an institutional review board affiliated with an accredited North Carolina medical school, at that school, an affiliated facility or a facility the review board approves. The review board keeps treatment records and reports each year to the North Carolina Medical Board, and buying or selling adult stem cells for valuable consideration for these treatments is a Class A1 misdemeanor, with listed exceptions. Source

Right to Try. North Carolina has its own Right to Try law. It lets a manufacturer make an investigational drug, biological product or device that has completed Phase I, is not yet FDA approved and is still in an FDA approved clinical trial available to a patient with a terminal illness who has considered FDA approved options, has a physician’s recommendation and gives written informed consent. A 2024 addition covers individualized investigational drugs, biological products or devices for a life-threatening or severely debilitating illness at eligible facilities. Source

Boards. North Carolina Medical Board, North Carolina Board of Nursing, North Carolina Board of Chiropractic Examiners, North Carolina Board of Physical Therapy Examiners.

Training in North Carolina. Charlotte.

North Dakota: full practice authority for NPs, collaboration without a written agreement for most PAs, and a Right to Try law for patients with a terminal illness; no state stem cell law found.

Nurse practitioners. North Dakota is a full practice authority state for nurse practitioners, according to AANP. Board of Nursing rules include diagnosing and prescribing legend drugs and controlled substances within APRN scope of practice, and the former rule on physician collaboration for prescriptive authority was repealed effective October 1, 2011. Source

Physician assistants. North Dakota law requires a physician assistant to collaborate with, consult with or refer to the appropriate member of the care team, and a written agreement is generally not required. A PA must practice at a licensed facility, a facility with a credentialing and privileging system, a physician-owned facility or practice, or a facility or practice approved by the board. A PA with less than 4,000 hours of practice at a board-approved facility or practice must execute a written collaborative agreement with a physician. Source

Stem cell and regenerative products. We did not find a North Dakota law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. North Dakota has its own Right to Try law, passed in 2015. It lets a manufacturer make an investigational drug, biological product or device that has completed phase one, is not FDA approved and is still in an FDA approved clinical trial available to a patient with a terminal illness, attested by the patient’s physician, who has considered FDA approved options, cannot join or was not accepted to a clinical trial within one hundred miles, has the physician’s recommendation, and gives written informed consent. Hospital inpatients are excluded. Source

Boards. North Dakota Board of Medicine, North Dakota Board of Nursing, North Dakota State Board of Chiropractic Examiners, North Dakota State Board of Physical Therapy.

Training in North Dakota. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Ohio: reduced practice authority for NPs, physician supervision for PAs, a Right to Try law, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in Ohio have reduced practice authority, per AANP. Ohio law lets a nurse practitioner practice only under a standard care arrangement with each physician or podiatrist the nurse collaborates with. Source

Physician assistants. Ohio physician assistants practice under physician supervision. Before supervising, a physician must sign a supervision agreement with each physician assistant stating that the physician agrees to supervise and is legally responsible for the physician assistant’s services. Source

Stem cell and regenerative products. We did not find an Ohio law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Ohio has its own Right to Try law, House Bill 290, effective April 6, 2017. It lets a manufacturer provide an investigational drug, product or device that has completed phase one of FDA clinical trials, remains under clinical investigation and is not FDA approved (schedule I controlled substances excluded) to a patient with a terminal condition, as determined by the patient’s own physician and one other physician who has examined the patient. The patient must first have considered FDA approved options. Source

Boards. State Medical Board of Ohio, Ohio Board of Nursing, Ohio State Chiropractic Board, Ohio Occupational Therapy, Physical Therapy, and Athletic Trainers Board.

Training in Ohio. Columbus, Cincinnati, Cleveland.

Oklahoma: restricted practice authority for NPs with an independent prescribing path under HB 2298, a 6,240 hour path to PA practice without supervision under HB 2584, a Right to Try law, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in Oklahoma have restricted practice authority, per AANP. Since November 1, 2025, HB 2298 lets an APRN with at least 6,240 clinical practice hours of physician-supervised prescriptive authority apply for independent prescriptive authority. An APRN approved for it no longer needs a supervising physician or a supervising physician agreement on file with the Board of Nursing. Source

Physician assistants. Oklahoma physician assistants without 6,240 verified hours of postgraduate clinical practice must practice under the supervision of a delegating physician, with a practice agreement on file with the Medical Board. Under HB 2584, effective August 29, 2025, a physician assistant whose 6,240 hours the Board has verified may practice without physician supervision. Only physician assistants supervised by a delegating physician under a practice agreement on file with the Medical Board may prescribe controlled medications in Schedules II through V. Source

Stem cell and regenerative products. We did not find an Oklahoma law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Oklahoma has its own Right to Try law, in effect since November 1, 2015, which lets a manufacturer make an investigational drug, biological product or device available to a patient with a terminal illness. The patient must have considered FDA approved options, been unable to join or not been accepted to a clinical trial within 100 miles, have a physician’s recommendation, and give written informed consent. A second law, SB 933, covers individualized investigational treatments from a manufacturer operating within an eligible facility, and it takes effect November 1, 2026. Source

Boards. Oklahoma State Board of Medical Licensure and Supervision, Oklahoma State Board of Osteopathic Examiners, Oklahoma Board of Nursing, Oklahoma Board of Chiropractic Examiners, Oklahoma State Board of Medical Licensure and Supervision, Physical Therapy Committee.

Training in Oklahoma. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Ontario: no AANP rating applies, physician assistants work under physician supervision, and Health Canada classes all cell therapies as drugs, while PRP that a practitioner such as a physician or dentist obtains from a patient and gives back to the same patient in a single procedure is regulated provincially.

Nurse practitioners. The AANP practice categories cover US jurisdictions and do not rate Ontario. The College of Nurses of Ontario registers nurse practitioners in its Extended Class and states that they are authorized to diagnose, order and interpret diagnostic tests, and prescribe medications and other treatments. Source

Physician assistants. The College of Physicians and Surgeons of Ontario (CPSO) began regulating physician assistants on April 1, 2025. CPSO states that physician assistants provide medical services within care teams under the supervision of a physician. They can only perform controlled acts through delegation and with appropriate supervision by a physician. Source

Health Canada cell therapy policy. Canada’s federal policy on autologous cell therapy products states that all cell therapies are drugs under the Food and Drugs Act. It states that “advanced” autologous cell therapy products must be licensed for sale and advertising through the market authorization process, except when they are for use in clinical research. Source

Health Canada PRP position (2019). Canada’s federal position, posted July 26, 2019, is that platelet rich plasma (PRP) meets the definition of a drug under the Food and Drugs Act. Its preparation falls under the practice of medicine and dentistry and is regulated at the provincial and territorial level when a practitioner, such as a physician or dentist, obtains it from a patient and gives it back to the same patient in a single procedure. Source

Boards. College of Physicians and Surgeons of Ontario, College of Nurses of Ontario, College of Chiropractors of Ontario, College of Physiotherapists of Ontario.

Training in Ontario (Canada). Toronto.

Oregon: full practice authority for NPs, collaboration agreements for physician associates, a Right to Try law that was repealed on January 2, 2022, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in Oregon have full practice authority, per AANP. The Oregon State Board of Nursing licenses nurse practitioners and may authorize them to write prescriptions, including for controlled substances in schedules II through V. Source

Physician assistants. Oregon law now uses the title physician associate. A physician associate may not practice medicine without a collaboration agreement signed by a physician, podiatric physician or employer. For those with fewer than 2,000 hours of post-graduate clinical experience, the agreement must include a plan for a minimum number of collaboration hours per month with a specified physician or podiatric physician. Source

Stem cell and regenerative products. We did not find an Oregon law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Oregon had its own Right to Try law, HB 2300 (2015), which let a practitioner offer an investigational product that is not FDA approved to a patient with a terminal disease, with protections that included a waiver of liability. Section 15 of the act repealed it on January 2, 2022. Source

Boards. Oregon Medical Board, Oregon State Board of Nursing, Oregon Board of Chiropractic Examiners, Oregon Board of Physical Therapy.

Training in Oregon. Portland.

Pennsylvania: reduced practice authority for NPs (CRNPs), physician supervision for PAs under a written agreement, a Right to Try law, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in Pennsylvania, titled certified registered nurse practitioners (CRNPs), have reduced practice authority, per AANP. State Board of Nursing rules describe CRNP practice in collaboration with a physician licensed in Pennsylvania under a collaborative agreement. Source

Physician assistants. Under State Board of Medicine rules, a physician assistant practices medicine with physician supervision under a written agreement filed with the board. The agreement describes the physician assistant’s scope of practice and the nature and degree of supervision. The supervising physician does not need to be physically present at all times, as long as the physician and physician assistant are, or can be, easily in contact with each other. Source

Stem cell and regenerative products. We did not find a Pennsylvania law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Pennsylvania has its own Right to Try law, Act 33 of 2017, for the use of investigational drugs, biological products and medical devices by terminally ill patients. An eligible patient has a terminal illness attested by the patient’s physician, has considered FDA approved options, could not join a clinical trial within 100 miles of home or was not accepted within one week, has the physician’s recommendation, and has given written informed consent. Hospital inpatients are not included. Source

Boards. Pennsylvania State Board of Medicine, Pennsylvania State Board of Osteopathic Medicine, Pennsylvania State Board of Nursing, Pennsylvania State Board of Chiropractic, Pennsylvania State Board of Physical Therapy.

Training in Pennsylvania. Philadelphia, Pittsburgh.

Puerto Rico: reduced practice for NPs, continuous physician supervision and no prescribing for physician assistants (Médicos Asistentes), and no Puerto Rico law written specifically for stem cell products found, while federal FDA rules apply to regenerative medicine products.

Nurse practitioners. Puerto Rico has reduced practice for nurse practitioners, according to the AANP. Puerto Rico’s nursing law lets a nurse practitioner work as a primary provider under protocols and collaborative agreements with a physician. Under those agreements, a nurse practitioner may order medications for diagnosed conditions, except controlled substances in categories I and II. Source

Physician assistants. Puerto Rico licenses physician assistants as Médicos Asistentes through the Junta de Licenciamiento y Disciplina Médica. A Médico Asistente practices medicine in a limited way under continuous supervision by a physician licensed in Puerto Rico, and one physician may supervise no more than two. Médicos Asistentes may not prescribe medications in Puerto Rico, and a physician must also sign their medical orders. Source

FDA rules for regenerative medicine products. Federal FDA law applies in Puerto Rico: the Food, Drug, and Cosmetic Act includes Puerto Rico in its definition of a State. FDA states that it regulates regenerative medicine products and that they require FDA licensure or approval to be marketed to consumers, and it names stem cells, stromal vascular fraction, umbilical cord blood, amniotic fluid, Wharton’s jelly, ortho-biologics and exosomes among the unapproved products. The only FDA approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood. Source

Boards. Junta de Licenciamiento y Disciplina Médica, Junta Examinadora de Enfermería, Junta Examinadora de Quiroprácticos, Junta Examinadora de Terapia Física.

Training in Puerto Rico. San Juan.

Quebec: no AANP rating applies, specialized nurse practitioners are licensed by the OIIQ, the only physician assistant regulation we found covers Canadian Forces physician assistants, and Health Canada classes all cell therapies as drugs, while PRP that a practitioner such as a physician or dentist obtains from a patient and gives back to the same patient in a single procedure is regulated provincially.

Nurse practitioners. The AANP practice categories cover US jurisdictions and do not rate Quebec. The Quebec government states that specialized nurse practitioners (IPS in French) hold a licence to practise issued by the Ordre des infirmières et infirmiers du Québec (OIIQ). They are authorized to diagnose illnesses, prescribe diagnostic examinations, determine and prescribe medical treatments, and prescribe medications. Source

Physician assistants. We did not find a Quebec regulator or regulation for civilian physician assistants as of September 2026. The only Quebec regulation we found covers Canadian Forces physician assistants. It sets which physician activities they may perform during their training or to maintain their competence. Source

Health Canada cell therapy policy. Canada’s federal policy on autologous cell therapy products states that all cell therapies are drugs under the Food and Drugs Act. It states that “advanced” autologous cell therapy products must be licensed for sale and advertising through the market authorization process, except when they are for use in clinical research. Source

Health Canada PRP position (2019). Canada’s federal position, posted July 26, 2019, is that platelet rich plasma (PRP) meets the definition of a drug under the Food and Drugs Act. Its preparation falls under the practice of medicine and dentistry and is regulated at the provincial and territorial level when a practitioner, such as a physician or dentist, obtains it from a patient and gives it back to the same patient in a single procedure. Source

Boards. Collège des médecins du Québec, Ordre des chiropraticiens du Québec, Ordre professionnel de la physiothérapie du Québec.

Training in Quebec (Canada). Montreal.

Rhode Island: full practice authority for NPs, physician collaboration for PAs, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in Rhode Island have full practice authority, per AANP. Rhode Island law states that APRNs are licensed, independent practitioners within standards established or recognized by the board of nursing. Source

Physician assistants. Rhode Island law requires physician assistants to practice in collaboration with physicians. Collaboration means consulting with or referring to an appropriate physician or other professional as the patient’s condition and the physician assistant’s education, competencies and experience indicate. A physician must be accessible at all times for consultation. Source

Stem cell and regenerative products. We did not find a Rhode Island law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Boards. Rhode Island Board of Medical Licensure and Discipline, Rhode Island Board of Nurse Registration and Nursing Education, Rhode Island Board of Licensure for Physician Assistants, Rhode Island State Board of Chiropractic Examiners, Rhode Island Board of Physical Therapy.

Training in Rhode Island. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

South Carolina: restricted practice authority for NPs, physician supervision for PAs, a Right to Try law, and a Board of Medical Examiners advisory opinion that calls stem cell use the practice of medicine and says a physician may not delegate the injection of HCT/Ps that are not FDA approved.

Nurse practitioners. Nurse practitioners in South Carolina have restricted practice authority, per AANP. South Carolina law requires a nurse practitioner who performs medical acts to do so under a practice agreement with a physician who must be readily available for consultation. Source

Physician assistants. South Carolina physician assistants perform medical acts within written scope of practice guidelines under physician supervision. The supervising physician is responsible for all aspects of the physician assistant’s practice. Supervision must be continuous but does not necessarily require the physician’s physical presence where services are given. Source

Board of Medical Examiners stem cell advisory opinion. This South Carolina Board of Medical Examiners advisory opinion, which is not a statute, states that using stem cells for any medical condition is the practice of medicine. Its standard of care for HCT/Ps includes exhausting FDA approved options first, keeping records, training, a history and physical exam, and informed consent on whether the HCT/P is FDA approved or experimental. A physician may not delegate the injection of HCT/Ps that are not FDA approved to any personnel, while APRNs and PAs may administer FDA approved HCT/Ps if their practice agreements or scope of practice guidelines include it. Source

Right to Try. South Carolina has its own Right to Try law, effective June 3, 2016, under which a manufacturer may make an investigational drug, biological product or device available to an eligible patient, and the patient may request it. An eligible patient has a terminal illness attested by a physician, has considered and exhausted FDA approved options, has the physician’s recommendation, and has given written informed consent. A manufacturer is not required to provide it. Source

Boards. South Carolina Board of Medical Examiners, South Carolina Board of Nursing, South Carolina Board of Chiropractic Examiners, South Carolina Board of Physical Therapy Examiners.

Training in South Carolina. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

South Dakota: full practice authority for NPs, a 6,000 hour path for PAs to practice without a collaborative agreement, a Right to Try law, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in South Dakota have full practice authority, per AANP. Among the licensing requirements, a nurse practitioner must have completed 1,040 practice hours as a licensed nurse practitioner or nurse midwife, or have a written collaborative agreement with a physician, nurse practitioner or nurse midwife to meet the 1,040 hour requirement. Source

Physician assistants. South Dakota law defines a physician assistant collaborative agreement as a signed contract setting the terms of collaboration between a physician and a physician assistant who has not filed an affidavit with the board attesting to at least 6,000 practice hours. A physician assistant certified by the National Commission on Certification of Physician Assistants who files that affidavit may practice without a collaborative agreement, under a 2025 change to the law. Source

Stem cell and regenerative products. We did not find a South Dakota law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. South Dakota has its own Right to Try law, passed in 2015 and amended in 2025, under which a manufacturer may make an investigational treatment available to an eligible patient, with or without compensation. That covers a drug, biological product or device that has completed phase one of an FDA approved clinical trial but is not yet FDA approved for general use, or an individualized treatment made for one patient from that patient’s genetic profile by a manufacturer in an eligible facility. An eligible patient has a life-threatening or severely debilitating condition attested by a physician, has considered FDA approved options, has the physician’s recommendation, and gives written informed consent, and no manufacturer or facility is required to provide it. Source

Boards. South Dakota Board of Medical and Osteopathic Examiners, South Dakota Board of Nursing, South Dakota Board of Chiropractic Examiners, South Dakota Board of Physical Therapy.

Training in South Dakota. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Tennessee: restricted practice authority for NPs, a PA law moving to physician collaboration, a Right to Try law, and Public Chapter 1016 (2026), which sets product, advertising notice and written consent rules for stem cell and regenerative therapy that is not FDA approved.

Nurse practitioners. Nurse practitioners in Tennessee have restricted practice authority, per AANP. Under Board of Nursing rules, an APRN who holds a certificate of fitness and prescribes must have a collaborating physician and must file a notice with the board naming that physician before prescribing. Source

Physician assistants. The Board of Physician Assistants rules posted by the Secretary of State, dated August 16, 2021, require a written protocol signed with a supervising physician and a designated primary supervising physician. Public Chapter 1042 (2024) rewrote the law around a collaborating physician: practice under protocols or, for a physician assistant the board endorses after at least 6,000 hours of documented postgraduate clinical experience, a collaborative agreement. Apart from rulemaking, that act takes effect on the effective date of its implementing rules. Source

HB 2246 / SB 2586 (2026), Public Chapter 1016. Since July 1, 2026, a medical or osteopathic physician may perform stem cell or regenerative medicine therapy that is not FDA approved if it is within the physician’s scope of practice and the products come only from a facility that meets the law’s product and facility standards. Each advertisement must carry a set notice that begins “THIS NOTICE MUST BE PROVIDED TO YOU UNDER TENNESSEE LAW”, and the physician must obtain a written consent form signed by the patient or the patient’s representative before the therapy. Adverse events must be reported, and the law does not apply to FDA approved investigational use, to hospitals and their outpatient clinics, or to therapy under the Right to Try Act. Source

Right to Try. Tennessee has its own Right to Try law, the Phil Timp-Amanda Wilcox Right to Try Act, effective July 1, 2015. As enacted, it lets a patient with an advanced illness, attested by the patient’s physician and confirmed by a second physician, use an investigational drug, biological product or device that has completed phase 1 of a clinical trial. The patient must have considered FDA approved options, be unable to enter or be accepted within one week into a clinical trial within 50 miles of home, have the physician’s recommendation, and give written informed consent. Source

Boards. Tennessee Board of Medical Examiners, Tennessee Board of Osteopathic Examination, Tennessee Board of Nursing, Tennessee Board of Physician Assistants, Tennessee Board of Chiropractic Examiners, Tennessee Board of Physical Therapy.

Training in Tennessee. Nashville.

Texas: restricted practice authority for NPs, physician delegation and supervision for PAs, a Right to Try law, and three adult stem cell laws (HB 177, HB 810 and HB 3148) that set rules for adult stem cell use, investigational stem cell treatment under IRB oversight, and a physician registry.

Nurse practitioners. Nurse practitioners in Texas have restricted practice authority, per AANP. Texas law lets a physician delegate the prescribing or ordering of drugs and devices to an APRN, acting under adequate physician supervision, through a prescriptive authority agreement. Source

Physician assistants. Texas physician assistants work under physician delegation and supervision. A physician may delegate the prescribing or ordering of drugs and devices to a physician assistant, acting under adequate physician supervision, through a prescriptive authority agreement. The delegating physician remains responsible for the delegated medical acts. Source

HB 810 (2017). A patient with a severe chronic disease or terminal illness listed in state rules and attested by the patient’s physician may access an investigational adult stem cell treatment, one under investigation in a clinical trial and not yet FDA approved for general use, if the physician has considered FDA approved options, found them unavailable or unlikely to help, and recommended or prescribed the treatment in writing. The patient must sign a written informed consent, and the treatment must be given directly by a physician certified by an institutional review board (IRB), under IRB oversight, at a licensed hospital, a licensed ambulatory surgical center, or a medical school. The IRB must keep a record on each patient and report each year to the Texas Medical Board. Source

HB 3148 (2019). The state must keep an investigational stem cell registry listing each physician who administers an investigational stem cell treatment under the law. The law does not bar a physician from using adult stem cells for their intended homologous use if the cells are produced by an FDA registered manufacturer and are commercially available. It also does not require IRB oversight of adult stem cells registered by the FDA for their intended homologous use. Source

HB 177 (2015). Anyone using adult stem cells in patient care must use adult stem cells that are properly manufactured and stored, and may only use them in a clinical trial approved by the FDA. A hospital may use adult stem cells in a procedure if a physician there finds the use appropriate, the patient consents in writing, those requirements are met, the manufacturing meets FDA current good manufacturing practices, and state and federal guidelines are followed. Source

Texas Medical Board IRB reporting rule. An institutional review board overseeing clinical trials of investigational stem cell treatments must send an annual report to the Texas Medical Board for the September 1 to August 31 period. The report includes findings, the number of patients, effects including all adverse events, the affiliated medical school or hospital, the treatment location, and the names of all physicians the IRB certified, with no patient identifying information. Source

Right to Try. Texas has its own Right to Try law, HB 21, effective June 16, 2015. A patient with a terminal illness whose physician has considered FDA approved options, found them unavailable or unlikely to prolong life, and recommended a specific class of investigational drug, biological product or device in writing may access it after signing a written informed consent. A manufacturer may make it available but is not required to, and if it does, it must provide it without receiving compensation. Source

Boards. Texas Medical Board, Texas Board of Nursing, Texas Physician Assistant Board, Texas Board of Chiropractic Examiners, Texas Board of Physical Therapy Examiners.

Training in Texas. Dallas, Houston, San Antonio, Austin.

Utah: full practice authority for NPs, and two placental tissue laws (SB 199 and SB 55) that set a written notice and supply rule for stem cell therapy that is not FDA approved.

Nurse practitioners. Nurse practitioners in Utah have full practice authority, per AANP. Utah law lets a licensed APRN prescribe or administer prescription drugs, including schedule II to V controlled substances, with narrower prescribing limits for nurse anesthetists. Source

Physician assistants. A Utah physician assistant with less than 8,500 hours of post-graduate clinical practice must practice under written practice-level policies and procedures on how collaboration will occur, and must collaborate with a physician for the first 4,000 hours. Between 4,000 and 8,500 hours, the physician assistant must have a written collaborative agreement with a physician or with a physician assistant who has more than 8,500 hours in the same specialty. Different rules apply in some cases, including physician assistants changing specialties. Source

SB 199 (2024). SB 199 (2024): A provider whose scope of practice includes stem cell therapy may perform a stem cell therapy that is not FDA approved if the provider first gives the patient a set written notice that begins “THIS NOTICE MUST BE PROVIDED TO YOU UNDER UTAH LAW”. The notice must be on paper at least 8.5 by 11 inches in at least 40 point type, be prominently displayed at the entrance and in an area visible to patients, and be included in any advertisement for the therapy. The provider must also obtain a signed consent form covering each item the law lists, including the nature of the treatment and its FDA approval status, alternatives, and serious risks and benefits, and a violation is unprofessional conduct. Source

SB 55 (2026). Since May 6, 2026, a person may supply HCT/Ps to a provider whose scope of practice includes stem cell therapy if, before the supply, the provider gives the person written confirmation that the provider will give the required notice to each patient whose stem cell therapy will use those products. Source

Right to Try. Utah has its own Right to Try law, in effect since May 12, 2015. A patient diagnosed by a physician with a terminal illness, or with an eligible illness that a physician determines presents a substantial and severely debilitating or life-threatening risk with no satisfactory conventional option, may obtain an investigational drug or device that has completed FDA Phase 1 testing. Access runs through an agreement with the manufacturer and the patient’s physician that includes an informed consent document. Source

Boards. Utah Medical Licensing Board (Division of Professional Licensing), Utah Board of Nursing and Certified Nurse Midwives (Division of Professional Licensing), Utah Chiropractic Physician Licensing Board (Division of Professional Licensing), Utah Physical and Occupational Therapy Licensing Board (Division of Professional Licensing).

Training in Utah. Salt Lake City.

Vermont: full practice authority for NPs after a collaboration period for newer APRNs, written practice agreements for PAs, and Act 61 (S.22, 2021), which sets a written notice, posting, advertising and disclosure rule for stem cell products that are not FDA approved.

Nurse practitioners. Nurse practitioners in Vermont have full practice authority, per AANP. Vermont law requires an APRN with fewer than 24 months and 2,400 hours of licensed advanced nursing practice in an initial role and population focus (or fewer than 12 months and 1,600 hours for an added one) to have a formal agreement with a collaborating provider. Until that requirement is met, the APRN may not engage in solo practice in that role. Source

Physician assistants. A Vermont physician assistant may practice only under a written practice agreement with a participating physician, signed by both. The agreement must cover communication, availability, decision making and periodic joint evaluation, keep the physician assistant within the physician assistant’s education, training and experience, and include a plan for a physician to be available for consultation at all times. Physician assistants are licensed by the State Board of Medical Practice. Source

S.22 (2021), Act 61. A practitioner licensed by the Board of Medical Practice or the Office of Professional Regulation who administers stem cell or stem cell-related products that are not FDA approved must give each patient a set written notice before the first use, beginning “THIS NOTICE MUST BE PROVIDED TO YOU UNDER VERMONT LAW”. The notice must be at least 8.5 by 11 inches in at least 40 point type, explain how to file a complaint, be prominently displayed at the entrance and in an area visible to patients, and be included in advertisements, and before each use the patient signs a disclosure form stating the product’s FDA approval status. Covered products include cells from sources such as adipose tissue, amniotic membrane and placenta, cell components or vesicles, and amniotic fluid, and a violation is unprofessional conduct. Source

Boards. Vermont Board of Medical Practice, Vermont Board of Osteopathic Physicians and Surgeons (Office of Professional Regulation), Vermont State Board of Nursing, Vermont Board of Chiropractic (Office of Professional Regulation), Vermont Office of Professional Regulation, Physical Therapists (advisor model, no board).

Training in Vermont. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Virginia: restricted practice authority for NPs with a three year path to practice without an agreement, patient care team collaboration for PAs, an expanded access (Right to Try) law, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in Virginia have restricted practice authority, per AANP. A Virginia nurse practitioner must maintain collaboration and consultation with at least one patient care team physician under a written or electronic practice agreement. After the equivalent of at least three years of full-time clinical experience and the required attestation, a nurse practitioner may practice without a practice agreement. Source

Physician assistants. Virginia physician assistants practice on patient care teams, where a patient care team physician or podiatrist provides collaboration and consultation to no more than six physician assistants at a time. A 2026 law adds a Code section that lets a physician assistant with the equivalent of at least three years of full-time clinical experience and a physician attestation practice without a practice agreement. The Code of Virginia lists that section with a contingent effective date. Source

Stem cell and regenerative products. We did not find a Virginia law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Virginia has its own Right to Try law, which the Code calls expanded access to investigational drugs, biological products, and devices. It covers a person with a terminal condition, attested by the person’s physician and confirmed by a second physician after an independent exam, who has considered all FDA approved options, has no reasonable opportunity to join an ongoing clinical trial, has the physician’s recommendation, and gives written informed consent. The product must have completed Phase I of a clinical trial, not be FDA approved for general use, and remain under investigation in a clinical trial. Source

Boards. Virginia Board of Medicine, Virginia Board of Nursing, Virginia Board of Physical Therapy.

Training in Virginia. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Washington: full practice authority for NPs, collaboration agreements for PAs, a Right to Try law, and ESHB 2356 (2018), which sets a written notice, posting, advertising and consent rule for stem cell therapy that is not FDA approved.

Nurse practitioners. Nurse practitioners in Washington have full practice authority, per AANP. Washington’s nursing rule calls the advanced registered nurse practitioner (ARNP) a licensed independent practitioner who diagnoses and manages conditions. State law lets an ARNP prescribe legend drugs and controlled substances, as set out in RCW 18.79.050, upon approval by the Board of Nursing. Source

Physician assistants. Before practicing, a Washington physician assistant must enter into a collaboration agreement that identifies at least one participating physician. A physician assistant with fewer than 4,000 hours of postgraduate clinical practice works under the supervision of a participating physician. One with 4,000 or more hours may work in collaboration with a participating physician if the physician assistant has completed 2,000 or more supervised hours in the chosen specialty. Source

ESHB 2356 (2018). ESHB 2356 (2018): A license holder who performs a stem cell therapy that is not FDA approved must first give the patient a set written notice that begins “THIS NOTICE MUST BE PROVIDED TO YOU UNDER WASHINGTON LAW”. The notice must be at least 8.5 by 11 inches in at least 40 point type, be prominently displayed at the entrance and in an area visible to patients, and be included in any advertisement, and the license holder must obtain a signed consent form covering each item the law lists, including the nature of the treatment and its FDA approval status, recognized alternatives, and recognized serious risks and benefits. Stem cell therapy here means any therapy using HCT/Ps, and a violation is unprofessional conduct. Source

Right to Try. Washington has its own Right to Try law, SSB 5035 (2017), for patients 18 or older who live in Washington and whose physician attests to a serious or immediately life-threatening disease or condition. A patient who has been told of all FDA approved options, has the physician’s recommendation, cannot reasonably join a clinical trial, and gives written informed consent may, with the physician, ask a manufacturer for an investigational product that has completed phase one and is currently in a later phase of an FDA approved clinical trial. The manufacturer may, but is not required to, provide it. Source

Boards. Washington Medical Commission, Board of Osteopathic Medicine and Surgery, Washington State Board of Nursing, Chiropractic Quality Assurance Commission, Board of Physical Therapy.

Training in Washington. Seattle.

West Virginia: reduced practice authority for NPs, physician collaboration for PAs, a Right to Try law, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in West Virginia have reduced practice authority, per AANP. West Virginia law lets an APRN prescribe under the terms of a written collaborative agreement with a physician. After at least three years in a documented collaborative relationship with prescriptive authority, the Board may authorize prescribing without a collaborative agreement. Source

Physician assistants. West Virginia law states that a physician assistant may not practice independent of a collaborating physician. A physician assistant practices in collaboration with physicians under a practice notification filed with, and activated by, the appropriate board. Source

Stem cell and regenerative products. We did not find a West Virginia law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. West Virginia has its own Right to Try law for a patient with a life-threatening or severely debilitating illness, attested by a physician, who has considered all FDA approved options, has a physician’s recommendation and documentation, and has given written informed consent; hospital inpatients are excluded. A manufacturer may, but is not required to, make an investigational drug, biological product, or device available, and state officials may not block an eligible patient’s access. The product must have completed phase one of a clinical trial and not be FDA approved for general use, or be made only for one patient based on that patient’s own genetic profile. Source

Boards. West Virginia Board of Medicine, West Virginia Board of Osteopathic Medicine, West Virginia Board of Registered Nurses, West Virginia Board of Chiropractic Examiners, West Virginia Board of Physical Therapy.

Training in West Virginia. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Wisconsin: reduced practice authority for NPs with an independent practice path under 2025 Wisconsin Act 17, physician direction or a collaborative agreement for PAs, a Right to Try law, and no law written specifically for stem cell products found as of September 2026.

Nurse practitioners. Nurse practitioners in Wisconsin have reduced practice authority, per AANP. Under Wisconsin law as amended by 2025 Wisconsin Act 17, effective September 1, 2026, an APRN practices only in collaboration with a physician or dentist unless the Board of Nursing verifies that the nurse meets the requirements for independent practice. Those include 3,840 hours of professional nursing in a clinical setting and 3,840 clinical hours of advanced practice nursing while working with a physician or dentist. Source

Physician assistants. A Wisconsin physician assistant who provides patient care must keep, and give the board on request, one of two records. One is evidence that, through the physician assistant’s employment, a physician is primarily responsible for the overall direction and management of the physician assistant’s professional activities. The other is a written collaborative agreement with a physician that describes the physician assistant’s individual scope of practice, subject to exceptions listed in the statute. Source

Stem cell and regenerative products. We did not find a Wisconsin law written specifically for stem cell or regenerative products as of September 2026. Federal FDA rules apply either way.

Right to Try. Wisconsin has its own Right to Try law, 2017 Wisconsin Act 165, effective March 30, 2018. It covers a patient diagnosed with a life-threatening disease or condition who has exhausted approved options, cannot join a clinical trial for the product, has the physician’s recommendation or prescription order and written verification, is aware of potential costs, and has given written informed consent. A manufacturer is authorized, but not required, to make available an investigational drug, device, or biological product that is not FDA approved or licensed, has completed a phase one clinical trial, and remains under investigation in an FDA approved phase 2 or 3 trial or is pending approval after phase 3. Source

Boards. Medical Examining Board, Board of Nursing, Physician Assistant Affiliated Credentialing Board, Chiropractic Examining Board, Physical Therapy Examining Board.

Training in Wisconsin. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Wyoming: full practice authority for NPs, practice-level collaboration for PAs, a Right to Try law, and the Stem Cell Freedom Act (SF0048, 2026), which sets state law conditions (physician registration, IRB approval or investigational status, manufacturing standards and written consent) for autologous mesenchymal stem cell therapy that is not FDA approved.

Nurse practitioners. Nurse practitioners in Wyoming have full practice authority, per AANP. Wyoming’s nurse practice act defines an APRN as a nurse who may prescribe, administer, dispense or provide medications, except schedule I drugs, and who is responsible for the direct care and management of patients. Source

Physician assistants. Wyoming law states that a physician assistant practices medicine and may collaborate with or refer to the appropriate member of a care team. The degree of collaboration is determined at the practice level, which may include decisions made by the employer, group, hospital service, or credentialing and privileging systems. Source

SF0048 (2026), Stem Cell Freedom Act. SF0048 (2026), Stem Cell Freedom Act: Since July 1, 2026, a physician may perform, and a patient may receive, autologous mesenchymal stem cell therapy that is not FDA approved if it is done under a current institutional review board approval or is an investigational product, the cells are manufactured and handled under current good manufacturing practice standards, and a physician-patient relationship exists. The physician must be registered with the Wyoming Board of Medicine to provide the therapy, and the patient must give written informed consent acknowledging the nature of the therapy, that it is not FDA approved, its potential benefits, risks and complications, and the patient’s financial responsibility. The therapy must be administered by a physician or under a physician’s direct supervision, and a physician assistant does not count as a physician under the act. Source

Right to Try. Wyoming has its own Right to Try law, effective July 1, 2015, for a patient with a terminal illness who has considered all FDA approved options, has a physician’s recommendation for an investigational drug, biological product or device, has given written informed consent, and has physician documentation. A manufacturer may make the product available but is not required to, and state officials may not block an eligible patient’s access. The Board of Medicine may not act against a physician’s license based solely on recommendations consistent with medical standards of care. Source

Boards. Wyoming Board of Medicine, Wyoming State Board of Nursing, Wyoming State Board of Chiropractic Examiners, Wyoming Board of Physical Therapy.

Training in Wyoming. Every course runs inside your own practice, with travel inside the quote. Ask about training at your practice.

Enroll in Our Regenerative Medicine Training Today

Know your state’s rules, then pick the training. Tell us your specialty and your state, and we’ll match you to an instructor and a date.

Every course runs at the instructor’s practice or inside yours.

Travel is inside the quote.

Request a date now
Call 888-623-3039

Talk to us

  • Call 888-623-3039
  • At an instructor's practice, or inside yours with travel inside the quote
  • Monday to Friday 9am to 5pm EST. Saturday 9am to 12pm. Sunday closed.

Important information

Read this before you book.

Six short notes on what the training is and is not. Open a heading to read it.

Education, not medical advice

Regen Med Academy provides education and training for licensed healthcare providers. Everything on this site is for educational purposes only. It is not medical advice, not a treatment recommendation, and not an offer to treat. Providers are responsible for practicing within the scope of their own license and their own state law.

Where a course can run

Courses are taught only in states where the modality is legal for the license you hold. State law in this field changes, sometimes more than once a year. Our reading of each state, with its sources and the date we checked, is on this page. It is a starting point, not legal advice. It is your responsibility to confirm the modality is legal in your state for your license. Do that before you book. The authority on your own scope is your licensing board, not us. State medical board contact details are published by the Federation of State Medical Boards.

Training on live patients

Procedures performed during training are performed on consenting patients, by licensed providers, under supervision. Participation is voluntary and outcomes vary.

Products and modalities

Some products and modalities discussed in these courses are not FDA approved or cleared for the uses described. Regen Med Academy does not manufacture, sell or endorse any product, and does not approve or clear any product. The FDA publishes guidance for patients and providers on regenerative medicine therapies.

What a certificate is, and is not

Regen Med Academy does not offer CMEs, credit hours or accreditation of any kind. What you receive is a Certificate of Completion. It records that you attended and performed the procedures under supervision. It is not a license, not a board certification, and it does not expand your scope of practice.

Coverage is yours to arrange

You are responsible for your own malpractice coverage. We will help you work out what to ask your carrier, and we recommend getting the answer in writing. Regen Med Academy does not provide, arrange or extend coverage to trainees, and nothing on this page is legal advice or an assurance of coverage.